Valvular & structural heart disease
Liver Extracellular Volume in Patients With Tricuspid Regurgitation: A Novel Prognostic Marker
Main finding · Composite of all-cause mortality and HF hospitalization, under medical managementResult — go to the resultAdjusted hazard ratio 1.82 95% CI 1.03–3.18Authors' conclusion
In our large real-world TR cohort, L-ECV appeared as a novel, powerful CMR marker of right HF with an independent and incremental prognostic value to stratify patients with TR at higher risk of events.
Study context
- Population
- Patients with TR referred to cardiac magnetic resonance (CMR) between 2019 and 2024 who had parametric mapping analysis for liver extracellular volume (L-ECV) quantificationpatients included
- Participants
- 462 patients
- Exposure
- High L-ECV vs low L-ECV
- Outcome
- Composite of:
- All-cause mortality and HF hospitalization
- Under medical management
- Follow-up
- Median 2.1 years
Main finding
As reported in the abstract
Adjusted hazard ratio
1.82
95% CI 1.03–3.18
P = 0.030
High L-ECVvs Low L-ECV
adjusted HR 1.82 (95% CI 1.03–3.18); P = 0.030
- Poorer survival free from the primary outcome with high L-ECV compared with low L-ECV
- P < 0.001
Observational data: associations, not effects.
Further findings
Baseline characteristics
- Median age
- 67 years
- Female
- 43%
- Median left ventricular ejection fraction (Q1-Q3)
- 51% (40%-59%)
- Median tricuspid regurgitant fraction (Q1-Q3)
- 21% (14%-33%)
- Median L-ECV (Q1-Q3)
- 31% (28%-35%)
- High L-ECV patients showed worse baseline status with more clinical and imaging signs of right heart failure (HF)
Incremental prognostic value vs TRI-SCORE
- L-ECV showed incremental prognostic value compared with TRI-SCORE in a nested Cox model
Original publication
Liver Extracellular Volume in Patients With Tricuspid Regurgitation: A Novel Prognostic Marker. JACC Cardiovasc Imaging. Published 26 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →